Does potassium cause constipation?

Potassium from food has not been shown to. We found no trial and no cohort that tests potassium from food against constipation. The link people run into comes from somewhere else. Constipation is a recognized sign of low blood potassium. And the binder drug patiromer, given to lower high blood potassium, about tripled the risk of constipation in a 2026 meta-analysis of 19 randomized trials in 3,627 patients (risk ratio 2.96). In absolute terms, 7.6 percent of people taking it in the pooled trials reported constipation.

Unsettled. For a banana, a bowl of beans or a potato, the honest answer is that we found no study that measured it. The search turned up four studies on dietary potassium and bowel habit, and all four were in people on dialysis. That is a gap in the research, and we will not fill it with a reassurance.

Established. Patiromer constipates. Across 19 randomized trials the risk ratio was 2.96, with a confidence interval from 1.21 to 7.22, which is wide because only a handful of patiromer trials reported constipation. The other common binder, sodium zirconium cyclosilicate, showed no statistically significant difference from control in constipation, nausea, vomiting or diarrhea.

Risk ratios against control, with 95% confidence intervals

ConstipationAny gut side effect

Right of the line means more side effects on the drug. Only the patiromer row has an interval that stays clear of no difference. The citrate row counts all gut side effects, because the review did not report constipation on its own. Sources: cards ev-kcon-01, ev-kcon-05 and ev-kcon-06 below.

What the trials found

Every randomized number on this question is about medicines that contain or remove potassium, in people who are ill. None of it is about food.

Potassium binders

The newest pooled analysis covers 19 trials and puts constipation on patiromer at almost three times the control rate. Its authors read the full trial reports and found the constipation described as mild to moderate in three of the four studies that reported it. The fourth did not grade it. An earlier pooling of phase II and III trials found 7.6 percent of people on patiromer reported constipation, which made it the most common gut side effect, ahead of diarrhea at 4.5 percent.

Share of people on patiromer who reported constipation

These are rates in the treated groups, so they include constipation that would have happened anyway. The trials reported most of it as mild to moderate. Sources: cards ev-kcon-04, ev-kcon-07 and ev-kcon-08 below.

Single trials sit around those numbers. In a 52-week trial in 306 people with type 2 diabetes and kidney disease, all already on blood pressure drugs that raise potassium, 6.3 percent had mild to moderate constipation. That trial had no placebo group, so the figure is an incidence and cannot be read as an effect. In people aged 65 and over in the OPAL-HK trial, constipation reached 15 percent in the first four weeks, when everyone took patiromer, and 7 percent in the eight weeks that followed.

A Cochrane review that pooled all potassium binders in chronic kidney disease was less sure. Four studies in 425 people gave a risk ratio of 1.58, with an interval from 0.71 to 3.52 that includes no effect. The reviewers rated that evidence low certainty.

Potassium salts as medicine

A Cochrane review of potassium citrate and related salts, taken for at least six months to prevent kidney stones, found more gut side effects than on control in four studies of 271 people. The risk ratio was 2.55 and did not reach statistical significance. The review did not report constipation separately.

Low blood potassium

The NIH Office of Dietary Supplements lists constipation, with fatigue, muscle weakness and malaise, as a feature of mild hypokalemia. That is an agency summary with no effect size attached. We found no trial of whether bringing a mildly low potassium back to normal relieves the constipation.

Kidney failure turns the question around

When the kidneys stop clearing potassium, the colon takes on part of the job, and constipation and high potassium start to travel together. Among 110 people on hemodialysis in China, 42.11 percent of those with high potassium were constipated against 20.83 percent of those with normal levels. In a Japanese survey of 472 dialysis patients, 63.1 percent of those on hemodialysis were constipated against 28.9 percent on peritoneal dialysis. Both studies are cross-sectional and cannot say which came first. A small non-randomized study points one way. In 13 hemodialysis patients, two weeks of the laxative bisacodyl lowered potassium between sessions from 5.9 to 5.5 mmol/L, and it did not change potassium in the control subjects.

Who should be careful

Not for everyone. If you have been started on patiromer for high potassium, constipation is its most common gut side effect, at 7.6 percent in the pooled trials and 15 percent in the first four weeks among people aged 65 and over. It is worth raising with the prescriber early, because in dialysis constipation goes together with higher potassium. If you take potassium chloride as a wax-matrix tablet, the approved label of glycopyrrolate warns that slower gut transit can make the tablet more likely to injure the bowel. The label is about one drug combination. Constipation also means slow transit, so tell whoever prescribed the potassium if you are constipated.

Potassium supplements and citrate salts mainly upset the stomach. NIH says potassium supplements can cause minor gastrointestinal side effects, and the citrate review found more gut complaints on the salt, short of statistical significance. Constipation was not singled out in either.

What expert bodies say

The NIH fact sheet on potassium names constipation as a sign of mild low blood potassium and says supplements can cause minor gut side effects. The glycopyrrolate label adds the warning about wax-matrix potassium chloride and slow transit. In the agency texts we searched, none links potassium from food to constipation in either direction.

How we searched

Searched: a local copy of the PubMed baseline, all study types, with six queries on 7 October 2026. They covered potassium or low potassium with constipation, ileus, bowel movements and laxatives, potassium salts and salt substitutes with gut side effects, potassium binders in meta-analyses, and dietary potassium with bowel habit. The broadest query returned 173 records, the binder query 16, and the dietary potassium query 4, all of them in dialysis. We also searched the NIH potassium fact sheet, a drug label database, ClinicalTrials.gov (no matching trials), and the open web for anything newer than the 2026 meta-analysis (nothing). None of the nine studies we cite has been retracted.

Included: four systematic reviews or meta-analyses, two randomized trials, three dialysis studies, two NIH passages and one drug label.

Excluded: seven other binder meta-analyses whose abstracts give no constipation figure, an observational study that pooled constipation and diarrhea drug starts, a review of secretory diarrhea, a salt substitute review and trial with no gut outcome, an uncontrolled potassium citrate tablet study, a fiber trial and a study of fecal potassium in healthy people.

What we read: abstracts, plus the safety section of the full text of the 2026 meta-analysis, from which two cards come.

What we could not get: the full texts of the earlier patiromer pooling and of the Cochrane binder review.

What would change this answer

Any study of potassium from food and constipation in people with working kidneys. A cohort with diet records and bowel habit would be enough to start, and none exists in what we searched.
A trial of correcting mild low potassium in people who are constipated. The agency link between the two has no effect size, and we found no test of the fix.
A head-to-head trial of patiromer against sodium zirconium cyclosilicate with constipation as a planned outcome. The current contrast comes from comparing each with control, and the patiromer interval is wide. ClinicalTrials.gov had nothing registered on potassium and constipation when we searched.

The rest of the nutrient, in one place. Potassium: the mineral most people under-eat, and the one some people must limit → What it does, how much you need, who runs short, and what too much does, with the evidence level shown on every line.

The full guide

Potassium: the mineral most people under-eat, and the one some people must limit

The same question for other foods (constipation)

Sources

ev-kcon-01 · Meta-analysis or systematic review · systematic review and meta-analysis of RCTs, random effects, search to June 2025 · n = 3,627
However, SZC was associated with a higher incidence of edema (RR, 2.92; 95% CI, 1.08 to 7.90) and patiromer with increased rates of constipation (RR, 2.96; 95% CI, 1.21 to 7.22) and hypokalemia (RR, 1.46; 95% CI, 1.05 to 2.03).
Who: patients with hyperkalemia in RCTs of sodium zirconium cyclosilicate (1,911) or patiromer (1,716)
Effect: patiromer: constipation RR 2.96 (95% CI 1.21 to 7.22), hypokalemia RR 1.46 (1.05 to 2.03); SZC: edema RR 2.92 (1.08 to 7.90)
Certainty: Wide interval; constipation pooled from a handful of patiromer trials.
Kidney360, 2026 · checked 2026-10-07 · we read the abstract
ev-kcon-02 · Meta-analysis or systematic review · systematic review and meta-analysis of RCTs, random effects · n = 1,911 on SZC
As summarized in Table 4, no statistically significant differences were observed between the SZC and control groups in the incidence of overall adverse events, serious adverse events, nausea, vomiting, diarrhea, constipation, or hypokalemia.
Who: patients with hyperkalemia in RCTs of sodium zirconium cyclosilicate vs control
Effect: constipation, nausea, vomiting, diarrhea: no statistically significant difference vs control; edema higher
Certainty: Absence of a significant difference, not proof of no effect.
Kidney360, 2026 · checked 2026-10-07 · we read the fulltext
ev-kcon-03 · Meta-analysis or systematic review · systematic review and meta-analysis of RCTs, narrative safety summary · n = 4 studies
Constipation was described as mild to moderate in three of the four studies,10,11,16 whereas Butler et al.13 did not specify the severity of this adverse event.
Who: patients with hyperkalemia in RCTs of patiromer that reported constipation
Effect: constipation severity mild to moderate in 3 of 4 trials; 1 trial did not grade severity
Certainty: Severity grading taken from the trials as reported.
Kidney360, 2026 · checked 2026-10-07 · we read the fulltext
ev-kcon-04 · Meta-analysis or systematic review · systematic review and meta-analysis of phase II and III trials · n = 6 studies
Analysis of pooled adverse effects from these trials indicates that patiromer was associated with more gastrointestinal upset (7.6% constipation, 4.5% diarrhea) and electrolyte depletion (7.1% hypomagnesemia), whereas ZS-9 was associated with the adverse effects of urinary tract infections (1.1%) and edema (0.9%).
Who: patients with hyperkalemia in phase II and III trials of patiromer and sodium zirconium cyclosilicate
Effect: patiromer: constipation 7.6%, diarrhea 4.5%, hypomagnesemia 7.1%; ZS-9: urinary tract infection 1.1%, edema 0.9%
Certainty: Pooled incidence in treated arms; heterogeneity high (I2 80.6 to 99.6% for efficacy).
Pharmacotherapy, 2017 · checked 2026-10-07 · we read the abstract
ev-kcon-05 · Meta-analysis or systematic review · Cochrane systematic review and meta-analysis of RCTs, GRADE · n = 425
Potassium binders had uncertain effects on constipation (4 studies, 425 participants: RR 1.58, 95% CI 0.71, 3.52; I2 = 0%; low certainty evidence) in CKD.
Who: adults with chronic kidney disease and chronic hyperkalemia, RCTs of calcium or sodium polystyrene sulfonate, patiromer or sodium zirconium cyclosilicate
Effect: constipation RR 1.58 (95% CI 0.71 to 3.52, 4 studies, I2 0%); nausea RR 2.10 (0.65 to 6.78); diarrhea RR 0.84 (0.47 to 1.48)
Certainty: Low certainty for all outcomes; trials not designed for GI outcomes.
Cochrane Database Syst Rev, 2020 · checked 2026-10-07 · we read the abstract
ev-kcon-06 · Meta-analysis or systematic review · Cochrane systematic review and meta-analysis of RCTs · n = 271
There were more gastrointestinal adverse events in the citrate group; however this was not significant (4 studies, 271 participants: RR 2.55, 95% CI 0.71 to 9.16).
Who: adults with calcium kidney stones in RCTs of potassium citrate, potassium-sodium citrate or potassium-magnesium citrate, at least 6 months
Effect: GI adverse events RR 2.55 (95% CI 0.71 to 9.16, 4 studies); dropouts due to adverse events RR 4.45 (1.28 to 15.50); main side effect upper GI disturbance
Certainty: Reporting quality moderate to poor; constipation not reported separately.
Cochrane Database Syst Rev, 2015 · checked 2026-10-07 · we read the abstract
ev-kcon-07 · Randomized controlled trial(s) · phase 2 multicentre open-label dose-ranging RCT (AMETHYST-DN) · n = 306
Over the 52 weeks, hypomagnesemia (7.2%) was the most common treatment-related adverse event, mild to moderate constipation (6.3%) was the most common gastrointestinal adverse event, and hypokalemia (<3.5 mEq/L) occurred in 5.6% of patients.
Who: outpatients with type 2 diabetes, eGFR 15 to under 60 and serum potassium above 5.0 mEq/L, all on RAAS inhibitors
Effect: constipation 6.3% over 52 weeks; hypomagnesemia 7.2%; hypokalemia 5.6%
Certainty: No placebo arm; incidence only.
JAMA, 2015 · checked 2026-10-07 · we read the abstract
ev-kcon-08 · Randomized controlled trial(s) · prespecified subgroup of a phase 3 RCT with randomized withdrawal · n = —
Mild-to-moderate constipation occurred in 15% (part A) and 7% (part B) of patients aged ≥65 years.
Who: patients aged 65 or older with chronic kidney disease and hyperkalemia taking RAAS inhibitors (OPAL-HK subgroup)
Effect: constipation 15% (part A, 4 weeks) and 7% (part B, 8 weeks); recurrent hyperkalemia 30% on patiromer vs 92% on placebo
Certainty: Subgroup analysis; part A was single-arm.
Am J Med, 2018 · checked 2026-10-07 · we read the abstract
ev-kcon-09 · Position of an expert body · agency fact sheet · n = —
Mild hypokalemia is characterized by constipation, fatigue, muscle weakness, and malaise [3].
Who: general population; hypokalemia affects up to 21% of hospitalized patients
Effect: constipation listed as a feature of mild hypokalemia; hypokalemia usually due to diuretics and other medications
Certainty: Agency summary of clinical reviews; no effect size.
NIH Office of Dietary Supplements, Potassium Fact Sheet for Health Professionals · checked 2026-10-07 · we read the section
ev-kcon-10 · Position of an expert body · agency fact sheet · n = —
Potassium supplements can cause minor gastrointestinal side effects [48].
Who: people taking potassium supplements, salt substitutes or potassium-containing medicines
Effect: minor GI side effects; small-bowel lesions with obstruction, bleeding and perforation with some potassium salt drugs
Certainty: Agency statement; no incidence figure.
NIH Office of Dietary Supplements, Potassium Fact Sheet for Health Professionals · checked 2026-10-07 · we read the section
ev-kcon-11 · Position of an expert body · FDA-approved drug label · n = —
Concomitant administration of glycopyrrolate injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
Who: people taking potassium chloride wax-matrix tablets with anticholinergic drugs
Effect: increased severity of potassium chloride-induced GI lesions
Certainty: Label text; the same logic applies to any cause of slow transit, constipation included.
Glycopyrrolate injection, FDA-approved label (DailyMed), effective 2026-05-20 · checked 2026-10-07 · we read the section
ev-kcon-12 · Observational data · cross-sectional study, 3-day dietary records · n = 110
However, the number of patients with constipation in group N was less than that in group H (20.83% vs. 42.11%, P = .018).
Who: maintenance hemodialysis patients, China
Effect: constipation 42.11% in the hyperkalemia group vs 20.83% in the normal potassium group (P = .018); fiber OR 0.766 per g for hyperkalemia (0.675 to 0.870)
Certainty: Cross-sectional; cannot show that constipation raises potassium.
J Ren Nutr, 2025 · checked 2026-10-07 · we read the abstract
ev-kcon-13 · Observational data · questionnaire survey with dietary records · n = 472
The frequency of constipation was 28.9% in 204 CAPD patients and 63.1% in 268 hemodialysis patients.
Who: 472 dialysis patients (204 CAPD, 268 hemodialysis)
Effect: constipation 63.1% hemodialysis vs 28.9% CAPD (relative risk 3.14); binder use 49% vs 3.4%; potassium intake 1.3 vs 1.8 g/day; fiber 5.9 vs 11.0 g/day
Certainty: Confounded by binders, fluid limits and diet.
Am J Kidney Dis, 2002 · checked 2026-10-07 · we read the abstract
ev-kcon-14 · Observational data · non-randomized before-and-after study · n = 13
Bisacodyl treatment had no effect on plasma K+ concentrations in control subjects, but significantly decreased the mean interdialytic plasma K+ concentration (from 5.9+/-0.2 to 5.5+/-0.2 mmol/l, P<0.0005) in haemodialysis patients, whereas plasma K+ concentration did not change during lactulose treatment.
Who: hemodialysis patients and controls; separate oral potassium load test in end-stage renal disease
Effect: mean interdialytic plasma potassium 5.9 to 5.5 mmol/L (P < 0.0005) on bisacodyl; no change on lactulose (5 patients) or in controls
Certainty: Small, non-randomized.
Nephrol Dial Transplant, 2003 · checked 2026-10-07 · we read the abstract
k-07 · Position of an expert body
Constipation, fatigue, muscle weakness, and malaise.
Who: people with hypokalemia
Effect: symptoms by severity
NIH Office of Dietary Supplements, Health Professional Fact Sheet: Potassium · checked 2026-09-15

How this page was made. Evidence was extracted from primary sources into cards, every number was re-checked against the source, and the text was written from those cards. Bioma Learn has no human medical reviewer at this time, and we say so rather than invent one. Methodology. This is information, not medical advice.